Praxis precision medicines to present at upcoming investor conferences

Boston, nov. 07, 2022 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:
PRAX Ratings Summary
PRAX Quant Ranking